๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

โœ Scribed by Kenneth S. Koeneman; Chinghai Kao; Song-Chu Ko; Ling Yang; Yoshitaka Wada; David F. Kallmes; Jay Y. Gillenwater; Haiyen E. Zhau; Leland W. K. Chung; Thomas A. Gardner

Publisher
Springer-Verlag
Year
2000
Tongue
English
Weight
314 KB
Volume
18
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Metastasis suppressor genes for prostate
Metastasis suppressor genes for prostate cancer
โœ Ichikawa, Tomohiko; Nihei, Naoki; Kuramochi, Hiroaki; Kawana, Yoko; Killary, Ann ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 348 KB ๐Ÿ‘ 2 views

To examine the role of human chromosomes in the development of metastatic prostate cancer, we introduced a copy of human chromosomes into highly metastatic Dunning R-3327 rat prostatic cancer cells by microcell-mediated chromosome transfer. Each microcell hybrid clones containing human chromosomes 8

Adenovirus p16 gene therapy for prostate
Adenovirus p16 gene therapy for prostate cancer
โœ James A. Allay; Mitchell S. Steiner; Yu Zhang; Christopher P. Reed; Jody Cockrof ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 828 KB
Human osteocalcin: a strong promoter for
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer
โœ Helen O. McCarthy; Jonathan A. Coulter; Jenny Worthington; Tracy Robson; David G ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 818 KB

## Abstract ## Background Gene therapy has been identified as a promising treatment strategy for hormone refractory prostate cancer (HRPC). We report, for the first time, the use of the human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in HRPC.